NMD670 safely improved muscle function and strength in a small clinical trial of people with myasthenia gravis (MG), the therapy’s developer, NMD Pharma, announced. “These trial results represent an important milestone for NMD Pharma as they provide the first clinical proof of mechanism for our novel ClC-1 inhibitor…
A new ambulatory center, operated by Virtis Health, has opened its doors in the Atlanta, Georgia, area for myasthenia gravis patients (MG) and others who require infusion treatments. Virtis is a division of Soleo Health, a pharmacy that specializes in the provision of infusion therapies to homes…
What do you do when life just gets to be too much? Too heavy? If you’re reading this, then I feel it’s safe to assume that you’re a fighter, so you likely do the same thing I do and just keep fighting, pushing forward. There is no throwing in of…
People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19 infection, yet the majority of patients are discharged without any complications, a single center study reports. “Immunosuppressive therapy was continued during COVID-19 infection,” and “most of hospitalized patients were discharged…
Two investigational UCB treatments for generalized myasthenia gravis (gMG) — zilucoplan and rozanolixizumab — continue to show benefits in gMG patients, according to recently reported findings from Phase 3 trials. Both delivered as subcutaneous (under-the-skin) injections, zilucoplan works by blocking an immune system protein called C5 that…
“My pet Fido makes me feel so much better. Where can I get him a service dog vest?” You can’t. Well, you can, but unless Fido is specifically trained to perform tasks related to your disability, you shouldn’t. And I’ll tell you why. I’ve had two trained service dogs since…
The U.S. Food and Drug Administration has granted orphan drug status to NMD670, an experimental oral therapy that NMD Pharma is developing as a potential treatment for myasthenia gravis (MG). The designation is given to therapies intended for treating rare diseases, defined as those affecting fewer than…
The European Commission has approved Ultomiris (ravulizumab) as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG). Eligible patients will be positive for antibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-causing antibody. Ultomiris is now the first long-acting C5 complement…
The caregiver. The parent. The big sister. The only child. The husband/wife/spouse. The honors student. The executive. The jock. The soldier. The patient. The flaky friend. The chronically ill. These are all titles and roles that society establishes for us, or we establish ourselves. We might be proud to…
Argenx has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of subcutaneous efgartigimod — an under-the-skin formulation of the active agent in Vyvgart — for the treatment of generalized myasthenia gravis (gMG). FDA approval would provide gMG patients with an additional delivery…
Get regular updates to your inbox.
